Effects of Mebendazole and Flutamide Combination in Prostate Cancer Cell Lines: a Comprehensive in Vitro Analysis
Cellular Physiology and Biochemistry · 23.08.2026 · 60 (4) · 458-472
DOI: 10.33594/000000883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Physiology and Biochemistry, online erschienen am 23.08.2026. Verfasst von Mohammad Reza Fattahi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Mebendazole, Flutamide, Antineoplastic Agents.
Abstract (Originalsprache)
Background/Aims: The aim of this research was to use Mebendazole as an anticancer candidate to reduce the dose of Flutamide and reduce its side effects.
Method
In this in vitro study, we evaluated the effect of Mebendazole, Flutamide and Mebendazole-Flutamide combination therapy in LNCaP, DU145 and PC3 cell lines as representatives of human prostate cancer. The assessment includes scratch-wound assay, colony formation assay, flow cytometric analysis of apoptosis and DNA cell cycle, real-time PCR (BAX/BCL2, E-cadherin, N-cadherin, Snail, HIF1α, VEGFC, KLK3, TUBB1 and TUBB3 genes).
Results
To determine IC50 levels, cell lines were exposed to different concentration of the drugs. Our data indicated that IC50 values for Mebendazole (55μM) and for 3 cell lines and flutamide (12μM and 10μM) for PC3 and LNCaP/DU145 respectively, with MTT were approved by flow cytometry in a dose and time-dependent manner which was as a consequence of cell cycle arrest at G1/S phase. Furthermore, for the first time, we offered that combination of mebendazole and flutamide produced a greater inhibitory effect on cell viability, colony formation, and migration than either agent alone at the tested concentrations. The combination treatment also increased apoptotic cell populations and upregulated the BAX/BCL2 mRNA ratio and E-cadherin expression in all three cell lines (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Pathology, Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Urology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
- UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, and Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, Sao Paulo, Brazil.
Zitieren
APA
Fattahi, M. R., Taheri, D., Inanloo, S. H., Mirzaei, A., Azodian Ghajar, H., Reis, L. O., & Aghamir, S. M. K. (2026). Effects of Mebendazole and Flutamide Combination in Prostate Cancer Cell Lines: a Comprehensive in Vitro Analysis. Cellular Physiology and Biochemistry, 60(4), 458-472. https://doi.org/10.33594/000000883
Vancouver
Fattahi MR, Taheri D, Inanloo SH, Mirzaei A, Azodian Ghajar H, Reis LO, et al. Effects of Mebendazole and Flutamide Combination in Prostate Cancer Cell Lines: a Comprehensive in Vitro Analysis. Cellular Physiology and Biochemistry. 2026;60(4):458-472. doi:10.33594/000000883
BibTeX
@article{Fattahi2026,
author = {Fattahi, Mohammad Reza and Taheri, Diana and Inanloo, Seyed Hassan and Mirzaei, Akram and Azodian Ghajar, Helia and Reis, Leonardo Oliveira and Aghamir, Seyed Mohammad Kazem},
title = {Effects of Mebendazole and Flutamide Combination in Prostate Cancer Cell Lines: a Comprehensive in Vitro Analysis},
journal = {Cellular Physiology and Biochemistry},
year = {2026},
volume = {60},
number = {4},
pages = {458--472},
doi = {10.33594/000000883}
}
EUVIMED